Rolek, B.; Haber, M.; Gajewska, M.; Rogula, S.; Pietrasik, A.; GÄ…secka, A.
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. J. Cardiovasc. Dev. Dis. 2023, 10, 322.
https://doi.org/10.3390/jcdd10080322
AMA Style
Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, GÄ…secka A.
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. Journal of Cardiovascular Development and Disease. 2023; 10(8):322.
https://doi.org/10.3390/jcdd10080322
Chicago/Turabian Style
Rolek, Bartosz, Mateusz Haber, Magdalena Gajewska, Sylwester Rogula, Arkadiusz Pietrasik, and Aleksandra GÄ…secka.
2023. "SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain" Journal of Cardiovascular Development and Disease 10, no. 8: 322.
https://doi.org/10.3390/jcdd10080322
APA Style
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & GÄ…secka, A.
(2023). SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. Journal of Cardiovascular Development and Disease, 10(8), 322.
https://doi.org/10.3390/jcdd10080322